** Shares of drug developer Seres Therapeutics MCRB.O rise 14.1% to 93 cents premarket
** Says the U.S. FDA has granted "Breakthrough Therapy" designation to its experimental treatment, SER-155
** The treatment helps reduce bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant to treat various types of blood cancers
** The transplant uses blood stem cells from a donor to replace bone marrow that's not producing enough healthy blood cells
** SER-155 was well-tolerated with no treatment-related serious adverse events in an early-stage study - MCRB
** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Co is actively seeking a partner to provide financial resources and other capabilities to support its goal to maximize the SER-155 program opportunity
** Up to last close, stock down 41.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。